Leerink Swann reissued their outperform rating on shares of Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) in a research note released on Thursday morning. They currently have a $113.00 target price on the pharmaceutical company’s stock.

Several other research firms have also recently weighed in on VRTX. Stifel Nicolaus decreased their target price on shares of Vertex Pharmaceuticals from $108.00 to $105.00 and set a buy rating for the company in a research note on Tuesday, August 16th. JMP Securities reissued a buy rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, August 16th. Maxim Group reissued a hold rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, August 16th. RBC Capital Markets reissued a buy rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, August 16th. Finally, Robert W. Baird reissued an outperform rating and issued a $128.00 target price on shares of Vertex Pharmaceuticals in a research note on Tuesday, August 16th. Eleven analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average price target of $118.45.

Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) opened at 91.69 on Thursday. Vertex Pharmaceuticals has a one year low of $75.90 and a one year high of $134.71. The company’s market cap is $22.72 billion. The firm has a 50-day moving average of $97.52 and a 200 day moving average of $89.51.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Wednesday, July 27th. The pharmaceutical company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.21 by $0.03. Vertex Pharmaceuticals had a negative net margin of 17.77% and a negative return on equity of 12.34%. The business earned $431.61 million during the quarter, compared to analysts’ expectations of $428.08 million. During the same period last year, the business earned ($0.54) earnings per share. The firm’s revenue was up 159.9% on a year-over-year basis. Equities research analysts anticipate that Vertex Pharmaceuticals will post $1.00 EPS for the current year.

In other Vertex Pharmaceuticals news, Director Joshua S. Boger sold 6,500 shares of Vertex Pharmaceuticals stock in a transaction dated Wednesday, September 14th. The stock was sold at an average price of $92.37, for a total value of $600,405.00. Following the transaction, the director now owns 274,725 shares in the company, valued at $25,376,348.25. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Joshua S. Boger sold 1,100 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, August 22nd. The shares were sold at an average price of $100.79, for a total value of $110,869.00. Following the completion of the transaction, the director now owns 268,225 shares in the company, valued at approximately $27,034,397.75. The disclosure for this sale can be found here. 1.90% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. FMR LLC boosted its position in Vertex Pharmaceuticals by 46.9% in the second quarter. FMR LLC now owns 22,227,104 shares of the pharmaceutical company’s stock worth $1,911,975,000 after buying an additional 7,092,351 shares in the last quarter. Capital World Investors boosted its position in Vertex Pharmaceuticals by 0.4% in the second quarter. Capital World Investors now owns 21,692,797 shares of the pharmaceutical company’s stock worth $1,866,014,000 after buying an additional 94,635 shares in the last quarter. Vanguard Group Inc. boosted its position in Vertex Pharmaceuticals by 2.2% in the second quarter. Vanguard Group Inc. now owns 15,265,175 shares of the pharmaceutical company’s stock worth $1,313,110,000 after buying an additional 329,337 shares in the last quarter. JPMorgan Chase & Co. boosted its position in Vertex Pharmaceuticals by 4.2% in the second quarter. JPMorgan Chase & Co. now owns 12,173,439 shares of the pharmaceutical company’s stock worth $1,047,161,000 after buying an additional 485,112 shares in the last quarter. Finally, State Street Corp boosted its position in Vertex Pharmaceuticals by 0.4% in the second quarter. State Street Corp now owns 9,825,708 shares of the pharmaceutical company’s stock worth $845,214,000 after buying an additional 35,700 shares in the last quarter. Hedge funds and other institutional investors own 96.26% of the company’s stock.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company operates in pharmaceuticals segment. Its business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

5 Day Chart for NASDAQ:VRTX

Receive News & Ratings for Vertex Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.